Protagonist Therapeutics
PTGX
149 hedge funds and large institutions have $1.67B invested in Protagonist Therapeutics in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 19 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 2 → 8 (+6)
132% more call options, than puts
Call options by funds: $46.3M | Put options by funds: $19.9M
105% more capital invested
Capital invested by funds: $817M → $1.67B (+$857M)
89% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 19
69% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 35
13% more funds holding
Funds holding: 132 → 149 (+17)
6.01% more ownership
Funds ownership: 97.59% → 103.59% (+6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$37.8M |
| 2 |
RI
RTW Investments
New York
|
+$26.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.6M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$15.6M |
| 5 |
SC
Samlyn Capital
New York
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$62.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15M |
| 3 |
Morgan Stanley
New York
|
-$11.6M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$11.6M |
| 5 |
Goldman Sachs
New York
|
-$9.47M |
PTGX Hedge Fund Activity: Q4 2021 in Review
149 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2021, worth a combined $1.67B — up 105% from $817M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PTGX positions and 19 closed out — a net gain of 17 holders — while 59 added to existing stakes and 35 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $37.8M. The largest seller was Point72 Asset Management, cutting an estimated $62.2M.
- 149 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2021, up from 132 in Q3 2021.
- Funds reported $1.67B of Protagonist Therapeutics stock for Q4 2021, up 105% quarter-over-quarter.
- 36 funds opened new Protagonist Therapeutics positions in Q4 2021 and 19 closed out, a net change of +17 holders.
- The largest Protagonist Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $37.8M added.
- The largest Protagonist Therapeutics seller in Q4 2021 was Point72 Asset Management, an estimated $62.2M sold.
Based on aggregated 13F filings for Q4 2021.